As a developmental biologist, I have always been interested in learning how cells decide what they are going to be and how they are assembled into functioning organs. To that end, my research explores how signaling pathways are integrated to coordinate cell fate decisions and allocate cell types during both organogenesis and regeneration.

In our lab at Cincinnati Children’s, my colleagues and I use mouse models and primary cell lines to answer questions about liver development and regeneration. We focus on the therapeutic potential of differentiated hepatocyte plasticity to augment or regenerate insufficient intrahepatic bile duct systems.

To date, we’ve made several important discoveries. In addition to establishing a three-dimensional blueprint for the formation of liver bile duct architecture, we’ve demonstrated that hepatocytes can switch their identity to build missing liver bile ducts. Also, my work showing that proper cell fate decisions stem from Notch signaling — which imparts feedback regulation of ligand and receptor asymmetric expression — continues to be a central concept in canonical Notch signaling.

I’m also involved in an interdisciplinary project with experts in liver organoid models and bioinformatics. Together, we’re working to produce a three-dimensional pediatric cell atlas for liver development and disease.

I am honored to be asked by the Alagille Syndrome Alliance to help organize the 2019 and 2021 scientific meetings focused on Alagille syndrome, an autosomal dominant inherited disorder associated with bile duct abnormalities and liver damage (among many other complications). My involvement in the fields of Notch biology, developmental biology and liver biology makes me uniquely qualified to bring together world leaders in each of these areas. Our goal is to comprehensively cover the multiple defects identified in patients with this rare genetic syndrome.